EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Prevalence of PD-L1 Expression in Non–Small Cell Lung Cancer: A Real-World Analysis From Jordan

Osama El Khatib iD, Nour Obeidat iD, Abeer Yaseen iD, Rnad Khader iD, Maram Al-Yagoub, Nour Haroon, Anas Zayed, Majed Ghlailat iD, Yazan Hamadneh iD, Laith Al-Showbaki iD, Hussam Haddad, Sameer Yaser und 13 weitere

JCO Global Oncology · 2026-05 · 12 (5)

DOI: 10.1200/go-26-00114 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JCO Global Oncology, 2026-05. Verfasst von Osama El Khatib und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, B7-H1 Antigen, Lung Neoplasms. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Lung cancer remains the leading cause of cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway have significantly improved survival outcomes in non–small cell lung cancer (NSCLC), and treatment selection is influenced by the degree of PD-L1 expression. Although ICI use began in 2017, there is a lack of data on PD-L1 expression in NSCLC among Jordanian patients. This study aimed to estimate the prevalence of PD-L1 expression and its association with demographic, clinical, and molecular characteristics, including EGFR mutation and ALK rearrangements. METHODS This retrospective observational study reviewed electronic medical records for all patients with lung cancer diagnosed at King Hussein Cancer Center from January 1, 2017, to April 1, 2024. Included patients had histologically confirmed NSCLC and were tested for PD-L1 expression. PD-L1 expression was considered positive if the tumor proportion score (TPS) was ≥1%. Descriptive statistics were performed to summarize patient characteristics. Comparisons between TPS 1%-49% and TPS ≥50% groups were performed using chi-square tests. RESULTS Of the 1,872 screened patients, 1,508 met the inclusion criteria and were included in the analysis. In this sample, the majority of patients were male (79%), former smokers (70%), presented with advanced disease (stage III/IV, 86%), and had adenocarcinoma histology (71%). Approximately 25% presented with squamous cell carcinoma. The prevalence of PD-L1 positivity was 68% (n = 1,022). Among the PD-L1–positive patients, 59% had TPS 1%-49% and 41% had TPS ≥50%. Among patients tested for EGFR mutation and ALK fusion, alterations were identified in 16.6% and 8.4% of tested patients, respectively. In PD-L1–positive tumors, EGFR wild-type status was significantly associated with high PD-L1 expression (TPS ≥50%) compared with EGFR-mutated tumors (56% v 44%, P = .007). CONCLUSION This first comprehensive analysis of PD-L1 prevalence in patients with NSCLC in Jordan demonstrates a relatively high prevalence of both PD-L1 positivity (≥1%) and high expression (≥50%) compared with reported data from other regions. Distinct molecular associations were observed, with higher PD-L1 expression in ALK-rearranged and EGFR wild-type tumors. These findings underscore the need for prospective and multicenter studies to further identify the biologic and clinical implications of PD-L1 expression in Jordanian patients with NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungB7-H1 AntigenLung NeoplasmsHumansFemaleJordanMaleRetrospective StudiesMiddle AgedAgedPrevalenceAdultAged, 80 and over

Substanzen

B7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
  • Cancer Control Office, King Hussein Cancer Center, Amman, Jordan.
  • School of Medicine, The University of Jordan, Amman, Jordan.
  • Division of Medical Oncology and Hematology, School of Medicine, The University of Jordan, Amman, Jordan.
  • Pathology Department, King Hussein Cancer Center, Amman, Jordan.
  • Department of Surgery, King Hussein Cancer Center, Amman, Jordan.

ORCID-Profile: Osama El Khatib, Nour Obeidat, Abeer Yaseen, Rnad Khader, Majed Ghlailat, Yazan Hamadneh, Laith Al-Showbaki, Naser Mahmoud, Riad Abdel Jalil, Zaid Abdel Rahman, Omar Shahin, Mohammad Ma'koseh, Khalid Halahleh, Akram Al-Ibraheem, Mohammed J Al-Jaghbeer, Majdi Hasan Aljadayeh, Faris Tamimi, Kamal Al-Rabi

Zitieren

APA

El Khatib, O., Obeidat, N., Yaseen, A., Khader, R., Al-Yagoub, M., Haroon, N., Zayed, A., Ghlailat, M., Hamadneh, Y., Al-Showbaki, L., Haddad, H., Yaser, S., Mahmoud, N., Abdel Jalil, R., Al-Batsh, T., Abdel Rahman, Z., Shahin, O., Ma'koseh, M., Halahleh, K., …, & Al-Rabi, K. (2026). Prevalence of PD-L1 Expression in Non–Small Cell Lung Cancer: A Real-World Analysis From Jordan. JCO Global Oncology, 12(5). https://doi.org/10.1200/go-26-00114

Vancouver

El Khatib O, Obeidat N, Yaseen A, Khader R, Al-Yagoub M, Haroon N, et al. Prevalence of PD-L1 Expression in Non–Small Cell Lung Cancer: A Real-World Analysis From Jordan. JCO Global Oncology. 2026;12(5). doi:10.1200/go-26-00114

BibTeX
@article{ElKhatib2026,
  author = {El Khatib, Osama and Obeidat, Nour and Yaseen, Abeer and Khader, Rnad and Al-Yagoub, Maram and Haroon, Nour and Zayed, Anas and Ghlailat, Majed and Hamadneh, Yazan and Al-Showbaki, Laith and Haddad, Hussam and Yaser, Sameer and Mahmoud, Naser and Abdel Jalil, Riad and Al-Batsh, Tamer and Abdel Rahman, Zaid and Shahin, Omar and Ma'koseh, Mohammad and Halahleh, Khalid and Al-Ibraheem, Akram and Al-Jaghbeer, Mohammed J and Aljadayeh, Majdi Hasan and Al Maani, Jihad and Tamimi, Faris and Al-Rabi, Kamal},
  title = {Prevalence of PD-L1 Expression in Non–Small Cell Lung Cancer: A Real-World Analysis From Jordan},
  journal = {JCO Global Oncology},
  year = {2026},
  volume = {12},
  number = {5},
  doi = {10.1200/go-26-00114}
}
Kostenlos starten →